Elecoglipron moves to Phase III: what the new oral GLP-1 trial means
AstraZeneca has moved elecoglipron into Phase III, adding a new future-tablet headline to the oral GLP-1 conversation.
18 June 2026 · 2 min readTreatment News
Articles on UK weight-loss treatment routes, provider checks, costs, safety, access and comparison decisions.
Most people who stop GLP-1 treatment eventually restart
New ENDO 2026 data shows many GLP-1 users stop and later restart, which makes switching, maintenance and repeat-review wording more important.
18 June 2026 · 2 min read
GLP-1 users are losing weight but moving less
New ENDO 2026 data suggests GLP-1 users may be losing weight while moving less, which makes routine and support questions more important on provider pages.
18 June 2026 · 2 min read
The UK’s First Oral GLP-1 Weight-Loss Treatment: Wegovy Pill Approved by MHRA
The MHRA approved the Wegovy pill on 11 June 2026 - a landmark in UK obesity treatment. Independent analysis of the clinical evidence, who qualifies, how costs compare,…
13 June 2026 · 5 min read